Read our latest updates & insights

Alteogen announces it has been granted a process patent for producing aflibercept biosimilar, ALT-L9.  Alteogen reports the process improves the productivity and quality of large-scale production of fusion proteins.

Sandoz announces agreement with Gan & Lee Pharmaceutical to commercialise biosimilar insulins.

JHL announces first patient in randomised Phase III study conducted in China. The trial is being conducted in patients with previously untreated diffuse large B-cell lymphoma.

Mycenax announces positive results from Ph I PK clinical trials, reporting the product met the primary endpoint in PK comparison.

Chong Kun Dang announces approval for biosimilar darbepoetin from the Ministry of Food and Drug Safety of South Korea. This is the first biosimilar darbepoetin to be approved in a highly regulated country.

Shanghai Henlius’ research team presented an update on its TmAb clinical program with Phase III trials underway in Poland, Ukraine, Phillippines and China.

Prestige announces licensing agreement with Cipla, granting Cipla exclusive rights to distribute and market Prestige’s TmAb biosimilar in emerging markets.

Fuji Pharma announces acquisition of 4.2% stake in Alvotech for roughly $50 million.

The NHS announces negotiations for the supply of adalimumab biosimilars have concluded with Amgen, Biogen, Mylan, Sandoz and AbbVie. This deal is predicted to save the NHS £300M per year.

Biocon announces EU marketing authorisation for biosimilar trastuzumub, Ogivri®. Ogivri® is indicated for the treatment of HER2 positive early breast cancer, metastatic breast cancer and metastic gastric cancer.